Achillion Pharmaceuticals, Inc, a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that the US Patent & Trademark Office has granted Achillion US Patent No 7,476,686 related to the Achillion NS4A antagonists to treat the hepatitis C virus (HCV). This new patent, entitled 'Substituted Aryl Thioureas and related compounds; inhibitors of viral replication', includes novel mechanism of action claims and expires in 2025.
The details can be read here.
No comments:
Post a Comment